Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Influenza Vaccine Response in Patients with Locally Advanced or Metastatic Melanoma

Trial Status: closed to accrual

This trial studies response to influenza vaccine in patients with melanoma that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or other places in the body (metastatic). After exposure to a potential pathogen or vaccine, the body’s white blood cells are mobilized to help defend the body. Some of these white blood cells are known as T cells. As the infection is passing, the immune system is left with a “memory” of the infection in the T cells, which can then recognize the pathogen much more quickly the next time the infection occurs. Memory T cells are also formed after vaccination. However, many aspects of memory T cell formation are unknown, especially for those T cells that help other cells, known as T helper cells or CD4 cells. T helper cell help is critical for later production of the proteins that help defend against influenza infection. Understanding the establishment of memory cells may help future efforts to develop better vaccines.